Molecular Simulations Ino and
Hewlett Packard present
Is your organization depending upon rational drug design to lead it toward the therapeutics of the future? Most of the leading pharmaceutical and biotechnology companies are. An ultimate goal of rational drug design is to understand and predict the relationship between biological activity and molecular structure. A better understanding of such relationships can increase the efficiency of the lead optimization and lead generation cycles in your organization. By attending this seminar series, your organization can benefit from learning about state-of-the-art techniques in: pharmacophore model generation, database search strategies, advanced QSAR techniques, computer-aided compound selection, molecular similarity, and pseudo-receptor model generation.
Strategies European Seminar Monday, 28 June Stockholm, Sweden Tuesday, 29 June Paris, France Wednesday, 30 June Frankfurt, Germany
in
Series
U.S. S e m i n a r
Drug Discovery A Free Technical Seminar Series
Thursday, ljuly London, England
Series
Monday, July 18 Cambridge, MA Tuesday, July 19 New Brunswick, NJ Wednesday, July 20 Research Triangle Park, NC Thursday, July 21 LaJolla,CA
Featured speakers for this series: Dr. Peter Sprague — BioCAD Corporation
Friday, July 22 Burlingame, CA
Dr. Anthony Hopfinger — University of Illinois Dr. Simon Kearsley — Merck Research Laboratories Dr. David Rogers — Molecular Simulations Inc.
g î ^ K f i | » ï e m i n à r é call {617} 2 2 9 - 9 8 0 0 | e^ct. 7 8 9 • To attend seminars in Europe call + 4 4 2 2 3 4 1 3 3 0 2 , ext. 3 5 ^^^^^^^^W
Corporate JHeeàouarteés: Molecular^ iimulations Inc. ' 1 6 New England Executive Park, Burlington, MA 0 1 8 0 3 CIRCLE 2 3 ON READER SERVICE CARD
IVloleatjIaur* Simulations* S o i l
I I (> N S
TIIROIGII
:
S I M l l. A 1
mL'Em
PACKARD
